Search Results - "Ravina, BM"

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations by Gewandter, Jennifer S., Dworkin, Robert H., Turk, Dennis C., McDermott, Michael P., Baron, Ralf, Gastonguay, Marc R., Gilron, Ian, Katz, Nathaniel P., Mehta, Cyrus, Raja, Srinivasa N., Senn, Stephen, Taylor, Charles, Cowan, Penney, Desjardins, Paul, Dimitrova, Rozalina, Dionne, Raymond, Farrar, John T., Hewitt, David J., Iyengar, Smriti, Jay, Gary W., Kalso, Eija, Kerns, Robert D., Leff, Richard, Leong, Michael, Petersen, Karin L., Ravina, Bernard M., Rauschkolb, Christine, Rice, Andrew S.C., Rowbotham, Michael C., Sampaio, Cristina, Sindrup, Søren H., Stauffer, Joseph W., Steigerwald, Ilona, Stewart, Jonathan, Tobias, Jeffrey, Treede, Rolf-Detlef, Wallace, Mark, White, Richard E.

“…This article presents general considerations discussed at an IMMPACT consensus meeting regarding proof-of-concept (POC) clinical trials and major POC trial…”
Get full text

DLB and PDD boundary issues : Diagnosis, treatment, molecular pathology, and biomarkers by LIPPA, C. F, DUDA, J. E, FAHN, S, FARMER, J. M, GALASKO, D, GALVIN, J. E, GOETZ, C. G, GROWDON, J. H, GWINN-HARDY, K. A, HARDY, J, HEUTINK, P, IWATSUBO, T, GROSSMAN, M, KOSAKA, K, LEE, V. M.-Y, LEVERENZ, J. B, MASLIAH, E, MCKEITH, I. G, NUSSBAUM, R. L, OLANOW, C. W, RAVINA, B. M, SINGLETON, A. B, TANNER, C. M, HURTIG, H. I, TROJANOWSKI, J. Q, WSZOLEK, Z. K, AARSLAND, D, BOEVE, B. F, BROOKS, D. J, DICKSON, D. W, DUBOIS, B, EMRE, M

“…For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that…”
Get full text

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease by Siepel, Françoise J., Brønnick, Kolbjørn S., Booij, Jan, Ravina, Bernard M., Lebedev, Alexander V., Pereira, Joana B., Grüner, Renate, Aarsland, Dag

“…ABSTRACT Cognitive impairment in Parkinson's disease (PD) is common and does directly impact patients' everyday functioning. However, the underlying mechanisms…”
Get full text

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment by Ravina, B M, Fagan, S C, Hart, R G, Hovinga, C A, Murphy, D D, Dawson, T M, Marler, J R

“…Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses…”
Get full text

Proof of concept studies for tissue-protective agents in multiple sclerosis by Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, PA, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW, Waubant, E

“…Background There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives We convened a group of MS…”
Get full text